research use only
Cat.No.S7905
| Related Targets | PD-1/PD-L1 CXCR AhR Immunology & Inflammation related CD markers Interleukins Anti-infection Antioxidant COX Histamine Receptor |
|---|---|
| Other STING Inhibitors | H-151 C-176 CCCP diABZI STING agonist-1 (tautomerism) STING inhibitor C-178 C-171 G10 (STING agonist-1) MSA-2 SN-001 ZSA-51 |
|
In vitro |
Water : 100 mg/mL
DMSO
: 20 mg/mL
(29.74 mM)
Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 672.4 | Formula | C20H24N10O13 P2·xNa+ |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 849214-04-6(freeacid) | -- | Storage of Stock Solutions |
|
|
| Synonyms | 3',3'-cyclic GMP-AMP, Cyclic GMP-AMP, cGAMP | Smiles | C1C2C(C(C(O2)N3C=NC4=C3N=C(NC4=O)N)O)OP(=O)(OCC5C(C(C(O5)N6C=NC7=C(N=CN=C76)N)O)OP(=O)(O1)O)O | ||
| Targets/IC50/Ki |
STING
|
|---|---|
| In vivo |
Sublingual immunization of mice with Bacillus anthracis protective antigen (PA) and the STING ligand 3′3′-cGAMP promotes PA-specific serum IgG Ab responses of the same magnitude as those induced after immunization with PA and the experimental adjuvants cholera toxin (CT). 3′3′-cGAMP also promotes serum anti-PA IgA and IgA-producing cells in the bone marrow. Furthermore, the saliva of mice immunized with 3′3′-cGAMP exhibits similar levels of PA-specific IgA Abs as groups immunized with CT as adjuvant. The adjuvant activity of 3′3′-cGAMP is associated with mixed Th1, Th2, and Th17 responses. 3′3′-cGAMP also induces rapid IFN-β and IL-10 responses in sublingual tissues and cervical lymph nodes, and TGF-β responses in the cervical lymph nodes, which can contribute to promoting IgA responses after sublingual immunization. |
References |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05705986 | Recruiting | Relapse Remitting Multiple Sclerosis |
Thomas Jefferson University |
February 26 2021 | -- |
| NCT02986867 | Completed | Urothelial Carcinoma|Melanoma|Cervical Carcinoma in Situ |
University of Texas Southwestern Medical Center |
June 13 2017 | Not Applicable |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.